TRIAL TO COMPARE ADJUVANT ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOTERE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项III期试验的主要目的是确定4个周期的阿霉素（A:60mg/m2）、泰索帝（T:60mg/m2）和环磷酰胺（C:600mg/m2）同时给予是否比4个周期的AC （A:60mg/m2和C:600mg/m2）和4个周期的T （100mg/m2）更有效地延长淋巴结阳性乳腺癌患者的无病生存期（DFS）和总生存期(S)；如果术后4个周期的AT （A:60mg/m2和T:60mg/m2）至少与上述两种含环磷酰胺的方案一样有效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of this phase III trial are to determine whether four cycles of post-operative Adriamycin (A:60mg/m2), Taxotere (T:60mg/m2), and Cyclophosphamide (C:600mg/m2) administered concurrently will more effectively prolong disease-free survival (DFS) and overall survival (S) of patients with node-positive breast cancer than will four cycles of AC (A:60mg/m2 and C:600mg/m2) followed by four cycles of T (100mg/m2); and if four cycles of post-operative AT (A:60mg/m2 and T:60mg/m2) is at least as efficacious as the above two regimens containing cyclophosphamide.